Case Report

Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report

Takashi Kawaguchi¹ , Satoru Iwase² , Hironori Takeuchi¹ , Ayako Ikeda³ , Yujiro Kuroda² , Naoko Sakata² , Megumi Umeda³ , Kaori Kobara³ , Tadaharu Matsunaga⁴ , Sakae Unezaki¹ and Yoshinori Nagumo³

¹  Department of Practical Pharmacy, School of Pharmacy, Tokyo University of Pharmacy & Life Sciences, 1432-1 Horinouchi, Hachioji-city, Tokyo, Japan

²  Department of Palliative Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan

³  Nagumo Clinic, 1-11-2 Ohsaki, Shinagawa-ku, Tokyo, Japan

⁴  Department of Breast Diseases, Tokyo Medical University Hachioji Medical Center, 1163 Tatemachi, Hachioji-city, Tokyo, Japan

author email corresponding author email

Cases Journal 2009, 2:9081doi:10.1186/1757-1626-2-9081

Published:	24 November 2009

Abstract

Chemotherapeutic agents are rarely used for symptom management in patients under palliative care setting. This is because chemotherapeutic agents not only have limited efficacy in palliative treatment but are also known to exert severe adverse effects. We describe our experience with a patient with metastatic breast cancer who was successfully treated with low-dose capecitabine, without the development of any severe toxicities and with significant improvement in activities of daily living (ADL) and quality of life (QOL).

The patient, a 43-year-old female, had breast cancer with liver, bone, and cutaneous metastases. She visited our clinic after a year-long hiatus during which she underwent alternative therapy. She presented with ulcerated lesions on the anterior chest and dyspnea due to malignant pleural effusion. After treatment for the latter, we administered capecitabine (600 mg/day) in accordance with the wishes of the patient and her attendants. The ulcerated lesions on the anterior chest, dyspnea, ADL and QOL improved significantly, without the development of any serious adverse effects. The findings of this case indicate that chemotherapy in the form of low-dose capecitabine monotherapy may be considered in patients under palliative care setting.